Agriculture in the Jazira region is facing an escalating crisis as the autumn farming season begins, amid rising diesel ...

You asked for a 'stylish LP,' but what you got was that familiar blue gradient.The buttons are rounded, and emoji icons are ...

Mayor Devrim Demir stressed the importance of strengthening ties between Rojava and Northern Kurdistan and developing ...

Continuous vertical measurements during the ALPACA experiment reveal that Fairbanks' wintertime smog is confined to a shallow ...

An LP is determined by 'order,' not 'sense''I made an LP, but I'm not getting any inquiries.''The design is beautiful, but ...

NVIDIA introduces a multi-GPU solver for decision optimization, scaling to 100 million variables and beyond, promising faster ...

FP8 LLM training has never matched full-precision accuracy due to a hidden mathematical flaw. MIT, CMU, and NVIDIA Research researchers identified the root cause -- a stale scaling-factor mismatch ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Many people who face a heightened ...